Mutant NRASG12V drives acute myeloid leukemia (AML) cell proliferation and self-renewal in a mutually exclusive manner. Previous studies demonstrated that AML cell proliferation and self-renewal are associated with differential NRASG12V transcript levels, but whether different NRASG12V protein levels dictate proliferative versus self-renewal phenotypes is not known. To address that knowledge gap, Kurata and colleagues engineered AML cell lines in which tetracycline-inducible NRASG12V expression levels are tunable using various doxycycline doses. The authors found that moderate NRASG12V protein expression promotes AML cell proliferation, whereas higher NRASG12V protein expression facilitates AML cell senescence and self-renewal. Using mass cytometry, the authors showed that abundances of several downstream NRASG12V effectors, including known stemness mediators such as β-catenin, increase in a dose-dependent fashion, whereas others, such as phosphorylated STAT1, are not dose-dependent. Overall, this study demonstrates that differential NRASG12V protein levels disparately drive AML cell proliferation and...
Skip Nav Destination
Highlights| November 03 2022
Selected Articles from This Issue
Online ISSN: 1557-3125
Print ISSN: 1541-7786
©2022 American Association for Cancer Research
American Association for Cancer Research
Mol Cancer Res (2022) 20 (11): 1589.
A commentary has been published: Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line
A commentary has been published: LncRNA A2M-AS1 Promotes Ferroptosis in Pancreatic Cancer via Interacting With PCBP3
A commentary has been published: DNA Methyltransferase 3B–Mediated Intratumoral Heterogeneity and Therapeutic Targeting in Breast Cancer Recurrence and Metastasis
A commentary has been published: Glutamine Metabolism Mediates Sensitivity to Respiratory Complex II Inhibition in Acute Myeloid Leukemia
- Views Icon Views
- Share Icon Share
- Search Site
Article Versions Icon
- Version of Record November 3 2022
Selected Articles from This Issue. Mol Cancer Res 1 November 2022; 20 (11): 1589. https://doi.org/10.1158/1541-7786.MCR-20-11-HI
Download citation file:
Don't already have an account? Register
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign in via your Institution